📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
45 announcements match the current filters (relevance ≥ 5).
ICRA Reaffirms Torrent Pharma's Credit Ratings at [ICRA] AA+ (Stable) and [ICRA] A1+
ICRA Limited has reaffirmed Torrent Pharmaceuticals' long-term credit rating for its banking facilities and Non-Convertible Debentures (NCDs) at [ICRA] AA+ with a stable outlook. The short-term rating for the company's commercial paper programme has also been reaffirmed at [ICRA] A1+. Furthermore, the [ICRA] A1+ rating was assigned to an enhanced amount within the commercial paper programme. These ratings indicate a high degree of safety regarding timely servicing of financial obligations and very low credit risk.
Key Highlights
Long-term rating for banking facilities and NCDs reaffirmed at [ICRA] AA+ with a Stable outlook
Short-term rating for commercial paper programme reaffirmed at [ICRA] A1+
New [ICRA] A1+ rating assigned to an enhanced limit of the commercial paper programme
Ratings reflect the company's strong financial profile and robust creditworthiness
👀 What to Watch
The reaffirmation of high credit ratings confirms the company's financial stability and low default risk; investors should maintain their positions as the credit profile remains strong.
Torrent Pharma to Raise up to ₹12,500 Crore via Non-Convertible Debentures (NCDs)
Torrent Pharmaceuticals has approved a massive fundraise of up to ₹12,500 crore through the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs). The issuance will be conducted in one or more tranches on a private placement basis. The NCDs are secured by a 1.1x cover on specified trademarks and designated accounts. This significant capital raise is likely intended for strategic purposes, such as large-scale acquisitions or refinancing existing debt.
Key Highlights
Approved issuance of NCDs aggregating up to ₹12,500 crore in one or more tranches.
Proposed issuance of up to 12,50,000 NCDs with a face value of ₹1,00,000 each.
Securities will be listed on the Wholesale Debt Market Segment of the National Stock Exchange (NSE).
Security includes a first ranking exclusive charge over specified trademarks with a minimum cover of 1.1x.
Coupon rates and specific maturity dates will be determined at the time of allotment.
👀 What to Watch
Investors should monitor the company's next steps as a fundraise of this magnitude often signals a major acquisition or significant expansion. Watch for the final coupon rates to understand the impact on the company's interest expense and debt-to-equity ratio.
Torrent Pharma to Raise Up to ₹12,500 Crore via Non-Convertible Debentures (NCDs)
Torrent Pharmaceuticals has approved a massive fundraise of up to ₹12,500 crore through the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs). The issuance will be conducted on a private placement basis in one or more tranches and will be listed on the NSE Wholesale Debt Market. The NCDs are backed by a 1.1x security cover involving specified trademarks and designated accounts. This significant capital raise points toward potential large-scale refinancing or upcoming inorganic growth opportunities.
Key Highlights
Approved issuance of NCDs aggregating up to ₹12,500 crore via private placement.
Proposed issuance of up to 12,50,000 NCDs with a face value of ₹1,00,000 each.
Security provided includes a first ranking exclusive charge over specified trademarks with a 1.1x cover.
The instruments will be listed on the Wholesale Debt Market Segment of the National Stock Exchange of India.
👀 What to Watch
Investors should monitor the specific end-use of these funds, as a raise of this magnitude often precedes a major acquisition or significant debt restructuring. Keep an eye on the company's leverage ratios and interest coverage once the coupon rates are finalized.
Torrent Pharma Credit Rating Affirmed at IND AA+ (Stable); New CP Rated IND A1+
India Ratings and Research has reaffirmed Torrent Pharmaceuticals' credit rating for its existing banking facilities and Non-Convertible Debentures (NCDs) at IND AA+ with a stable outlook. Additionally, the agency has assigned a top-tier rating of IND A1+ for the company's proposed Commercial Paper program. These ratings reflect the company's strong financial profile and high creditworthiness within the pharmaceutical sector. The stable outlook suggests that the agency expects the company to maintain its credit profile in the medium term.
Key Highlights
India Ratings affirmed the existing issuer rating and NCDs at IND AA+ with a Stable outlook
A new credit rating of IND A1+ was assigned to the company's proposed Commercial Paper program
The affirmation covers all existing banking facilities, ensuring continued access to capital at competitive rates
The IND AA+ rating signifies a very high degree of safety regarding timely servicing of financial obligations
The assignment of IND A1+ for Commercial Paper indicates the highest degree of safety for short-term debt
👀 What to Watch
Investors should view this as a confirmation of the company's financial stability and disciplined balance sheet management. The high credit ratings will help the company maintain low borrowing costs for its future expansion or working capital needs.
Torrent Pharma acquires 1,317 shares of J.B. Chemicals at ₹1639.18 per share
Torrent Pharmaceuticals has acquired 1,317 equity shares of J.B. Chemicals & Pharmaceuticals Limited on December 5th, 2025. The acquisition was made through an open offer at a price of ₹1639.18 per equity share. This acquisition is in accordance with SEBI regulations regarding substantial acquisition of shares and takeovers. Investors should note this strategic move as it could potentially impact Torrent Pharma's future growth and market position.
Key Highlights
Acquired 1,317 equity shares of J.B. Chemicals
Acquisition price of ₹1639.18 per share
Acquisition date: December 5th, 2025
👀 What to Watch
Investors should monitor Torrent Pharma's future announcements and financial performance to assess the impact of this acquisition. Consider reviewing JB Chemicals' performance as well.
